Search Results - "Swinnen, L.J."

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study by de Vos, S., Swinnen, L.J., Wang, D., Reid, E., Fowler, N., Cordero, J., Dunbar, M., Enschede, S.H., Nolan, C., Petrich, A.M., Ross, J.A., Salem, A.H., Verdugo, M., Agarwal, S., Zhou, L., Kozloff, M., Nastoupil, L.J., Flowers, C.R.

“…Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic lymphocytic leukemia. We…”
Get full text

Donor‐Transmitted Malignancies in Organ Transplantation: Assessment of Clinical Risk by Nalesnik, M. A., Woodle, E. S., DiMaio, J. M., Vasudev, B., Teperman, L. W., Covington, S., Taranto, S., Gockerman, J. P., Shapiro, R., Sharma, V., Swinnen, L. J., Yoshida, A., Ison, M. G.

“…The continuing organ shortage requires evaluation of all potential donors, including those with malignant disease. In the United States, no organized approach…”
Get full text

Diagnosis and treatment of transplant-related lymphoma by Swinnen, L.J.

“…Immunodeficiency-related B-cell disorders are seen after organ transplantation and in congenital and acquired immunodeficiency states. Post-transplant…”
Get full text

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY by Swinnen, L.J., Flowers, C.R., Wang, D., Reid, E., Fowler, N., Cordero, J., Dunbar, M., Enschede, S., Nolan, C., Petrich, A.M., Ross, J., Salem, A.H., Verdugo, M., Wong, S., Zhou, L., Kozloff, M., Nastoupil, L., Vos, S.

Get full text

Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen by Bolaños-Meade, J, Luznik, L, Muth, M, Matsui, W H, Huff, C A, Smith, B D, Levy, M Y, Kasamon, Y L, Swinnen, L J, Powell, J D, Brodsky, R A, Ambinder, R F, Jones, R J, Fuchs, E J

“…Graft failure after allogeneic blood or marrow transplantation, although generally uncommon, can be a devastating complication. This report includes the…”
Get full text

CpG Methylation of the Major Epstein-Barr Virus Latency Promoter in Burkitt's Lymphoma and Hodgkin's Disease by Robertson, K.D., Manns, A., Swinnen, L.J., Zong, J.C., Gulley, M.L., Ambinder, R.F.

“…The Epstein-Barr virus (EBV) latency C promoter drives expression of a family of viral proteins commonly targeted by CD8 cytotoxic T cells. These proteins are…”
Get full text